Cardiometabolic
Treating hypertension in pregnancy is possible. Making it routine care is the policy challenge
A new ACC expert analysis sets out a practical approach to antihypertensive medication use in pregnancy and lactation, naming extended-release nifedipine and labetalol as preferred options in pregnancy, and nifedipine, amlodipine, enalapril and labetalol as preferred options during lactation. The clinical message is clear. The policy message is bigger: pregnant and postpartum patients need safe…
Sleep is now cardiovascular prevention. Health systems still treat it like lifestyle advice
The GLP-1 boom still needs exercise policy
Pharmacists are becoming the front door for cardiometabolic care. Policy is still treating them like the back office
Dementia prevention has a cardiometabolic blind spot
New nicotine products could become the next major cardiovascular policy failure
Childhood obesity is the next cardiometabolic crisis already unfolding
BMI is not enough. Cardiometabolic risk is hiding in where fat lives
Resistant hypertension may need a diagnostic revolution, not just another drug
When diabetes tech fails, personalised care fails with it
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.